Pharvaris N.V.
Pharvaris develops clinical-stage oral medicines for hereditary angioedema and related diseases.
Overview
Latest results
Jan–Jun 2026 · Reported in EUR
Latest financial publication
H1 2026 results
Investment Thesis
Positive prevention data bring the launch question closer
European Tech Equities analysis ·
An oral option has to win a place in everyday care
Pharvaris N.V. is developing deucrictibant for both treating hereditary angioedema attacks and preventing them. A convenient oral medicine could appeal to patients and doctors if it controls attacks reliably. The investment case is moving from whether the drug works towards whether approvals, reimbursement and prescribing can create a sustainable business. The two formulations have different regulatory paths.
The prevention trial strengthens the argument
On 8 September, Pharvaris reported that its 85-participant CHAPTER-3 study met the primary endpoint. Over 24 weeks, the extended-release treatment reduced the mean monthly attack rate by 83% relative to placebo. That is substantial evidence within this trial, although it does not establish superiority to competing drugs tested elsewhere. The company plans a U.S. prevention filing in H1 2027; its separate on-demand application has an FDA decision date of 23 April 2027.
Convenience still needs a reimbursement case
Rising global medicine spending provides a supportive backdrop, but the reachable market is patients with HAE who can obtain the drug. In the U.S. and Europe, the commercial test is whether fewer attacks and an oral regimen persuade doctors, patients and payers to change treatment. A prevention prescription could generate repeat revenue, provided patients continue taking the medicine and health systems accept its net price. Europe also requires country-by-country access work after regulatory approval.
Launch preparation is already expensive
Pharvaris had €318.3 million in cash at the end of June, following financing in May. It recorded no product revenue and a €95.1 million operating loss in the first half. Management expects funding to extend into 2028. The cash provides time for regulatory work and launch preparation, but a delay in sales would leave commercial costs arriving before the revenue meant to pay for them.
Separate approval from a successful launch
The next valuation step is to estimate how many patients might switch, how quickly access could expand and what net revenue remains after discounts and selling costs. Positive Phase 3 data reduce one important uncertainty; they do not remove approval or commercial risk. A sensible case should also keep the on-demand and prevention opportunities separate, allowing for overlap in patients rather than counting the same market twice.
What would weaken the case
- Regulators request additional work or impose restrictions that narrow the intended patient population.
- Patients and payers favour established alternatives despite the oral formulation.
- Launch spending rises while reimbursement or prescribing takes longer than expected.
Sources
Financials
The business in numbers
Latest
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt = debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
H1 2026 IFRS interim statements and management discussion. No product revenue: the company is in clinical development. Cash includes financing proceeds and does not represent earnings. Debt includes reported borrowings and lease liabilities, excluding trade and other operating payables.
Half-year
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt = debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
H1 2026 IFRS interim statements and management discussion. No product revenue: the company is in clinical development. Cash includes financing proceeds and does not represent earnings. Debt includes reported borrowings and lease liabilities, excluding trade and other operating payables.
Performance
About these figures
Dates link to the original reports. Bars compare the same period a year earlier, on a consistent accounting basis. Arrows show whether the number rose or fell, not whether it is good or bad for the business.
Research & updates
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
Company publications
Pharvaris N.V. · H1 2026 financial report
Interviews
Interviews are coming soon
No interviews with Pharvaris N.V. have been published yet.
Sources
Sources & data dates
Financial figures link to the company’s publications and retain their reporting period. Share prices have their own closing dates.
H1 2026 · Published Aug 12, 2026 · Checked Sep 14, 2026
Checked 2026-09-14
Checked 2026-09-14
Checked 2026-09-14
Checked 2026-09-14